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Behçet disease is a heterogeneous, multisystem inflammatory disorder; vascular involvement has been considered to result
from systemic vasculitis, which most frequently affects veins and occurs in 5% to 10% of these patients. However, superior
vena cava (SVC) involvement is rare; it accounts for only 6% of the cases. The aim of this article is to a report on a case of
SVC recanalization through the use of fibrinolysis and self-expanding stents as treatment of life-threatening SVC
syndrome in a young male patient with Behçet disease. ( J Vasc Surg 2005;41:548-51.)Behçet disease is a heterogeneous, multisystem inflam-
matory disorder with a chronic and recurrent course, which
typically consists of recurrent oral and genital ulcerations
and uveitis; vascular involvement has been considered to
result from systemic vasculitis, which involves immuno-
complexes in the vessel wall and occurs in 5% to 10% of
these patients.1,2 The inflammatory vasculitis frequently
affects veins and most often results in venous thrombosis of
the upper and lower extremity; conversely, superior vena
cava (SVC) involvement is rare and accounts only for 9.8%
of cases.3,4 Until recently, open surgery was considered the
primary method of treatment for symptomatic SVC ob-
struction of nonmalignant etiology, with percutaneous
transluminal angioplasty and stent procedure used second-
arily to maintain patency of vein grafts.5 However, over the
last decade, encouraging results with endovascular proce-
dures have prompted us to use primarily the endovascular
approach in selected patients.6 We report on a case of SVC
recanalization in a young male patient with SVC syndrome
(SVCS) affected by Behçet disease.
CASE REPORT
A 25-year-old male patient from North Africa with Behçet
disease was referred to our department of surgery with a history of
persistent dyspnea and chest pain. Physical examination revealed
acneiform nodules and swelling of his arms and neck. His medical
therapy had consisted of immunosuppressive and steroid therapy
for 6 months. In addition, venous collateral structures were de-
tected in his neck and anterior thoracic wall. Uveitis was confirmed
on ophthalmologic examination. The results of laboratory tests
were as follows: erythrocyte sedimentation rate was 85 mm/h,
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548white blood cell count was 8.1 109/L, hemoglobin was 12 g/L,
serum alkaline phosphatase was 221 U/L (reference range, 100-
290 U/L), and -glutamyl transferase was 87 U/L (reference
range, 9-52 U/L). The values of anticardiolipin immunoglobulin
G, lupus anticoagulant, protein S, protein C, antithrombin III,
fibrinogen, factor V-Leyden, and factor VIII were normal, as were
antinuclear antibodies. No previous central line was used in this
patient. Chest radiograph did not show any enlargement of the
mediastinum. Computed tomographic angiography (CT-A) ex-
cluded the presence of a mediastinal mass and showed the obstruc-
tion of the SVC. This was confirmed by bilateral upper arm digital
venography (DV) that showed the patency of the axillary and
subclavian veins (Fig 1) and obstruction of the innominate veins
(Fig 2). Ultrasound examination did not reveal any other localiza-
tion of vein thrombosis. We scheduled an endovascular recanaliza-
tion procedure of the SVC. The procedure was performed with the
patient under local anesthesia in the angiographic suite (equipped
with a fluoroscopic machine: Isocentric mobile C-arm; Siemens,
Munich, Germany) and was performed by an interventional team
assisted by an anesthesiologist for cardiocirculatory and airway
support. Initially we used catheter-directed intravenous locore-
gional fibrinolysis with urokinase for 24 hours. Successive DV
showed bilateral recanalization of the innominate veins with per-
sistent obstruction of the SVC; thereafter, we stented the SVC with
an 18-mm Palmaz large balloon-expandable stent (Cordis Corpo-
ration, Miami, Fla). The final DV control confirmed the complete
revascularization of the SVC (Fig 3). During hospitalization, in-
travenous heparin (22,000 IU/24 h) was administered for 48
hours, and values were maintained at greater than 1.5 times the
normal values of the prothrombin time and activated partial pro-
thrombin time. Thereafter, warfarin therapy was begun. Two
months later, the patient was readmitted with recurrent clinical
signs of SVC obstruction (bilateral arm swelling). DV control
showed thrombosis of the SVC, and the patient was immediately
treated with fibrinolysis. Twenty-four hours later, the DV control
showed successful recanalization of the stent without signs of
device complication, such as hyperplasia or intrastent dominant
stricture. The patient was discharged with warfarin, immunosup-
pressive drugs, and steroids. We then scheduled CT-A control at 1,
3, and 6 months after the procedure and then yearly; the last
follow-up CT-A control at 36 months confirmed the patency of
graph
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time the patient had no symptoms of venous disease.
DISCUSSION
SVCS is generally caused by SVC stenosis or occlusion
due to an underlying primary thoracic malignancy.5,6 Be-
hçet disease is a chronic relapsing systemic vasculitis in
which disease affects many systems and causes hypercoagu-
lability. CT-A and magnetic resonance venography imag-
ing are excellent diagnostic tools when SVC thrombosis is
suspected; venography is mainly used for clarifying dubious
cases of venous thrombosis.4,7 Vasculitic (large vein vascu-
litis) and thrombotic (abnormalities of coagulation or fi-
brinolytic activity) pathogenesis are both well known as
Fig 1. Preprocedural computed tomographic angio
Fig 2. Digital venography of the upper extremities con
with thrombosis of the superior vena cava and innominapredispositions for SVC thrombosis in Behçet disease; SVCthrombosis was observed in this case as the only venous
manifestation of Behçet disease.1-4 In our patient, CT-A
and venography findings were in favor of involvement of
the SVC and innominate veins. Because SVCS is mainly
caused by advanced lung and mediastinal cancers, it has
generally been associated with poor prognosis and has been
treated with radiation therapy, chemotherapy, or both be-
cause en-bloc tumor and caval replacement has been re-
ported to be too hazardous. Therefore, an endovascular
treatment of the brachiocephalic district has now become
the procedure of choice because it is less invasive, simpler,
and safer, as shown in our series and in other reports.8
Initially, endovascular procedures to treat SVCS involved
percutaneous transluminal angioplasty alone; the use of
y revealed the obstruction of the superior vena cava.
d bilateral patency of the axillary and subclavian veins,
ins.firmemetallic stents was first reported in 1986 and, more re-
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critical patients for SVCS, with a secondary patency rate of
80% after a mean follow-up of 16 months.6,8,9 The stenting
technique offers 2 important advantages: (1) it is well
tolerated, with immediate relief of the symptoms and pro-
longed duration of the response, and (2) it also allows the
patient to overcome a clinically critical situation rapidly,
making it easier to start adjuvant therapy promptly.5 We
used the endovascular technique to treat malignant in-
volvement of the subclavian and innominate veins and,
more recently, used stent-grafts to exclude traumatic inju-
ries of the inferior vena cava. In this patient, urokinase
infusion was used before the endovascular procedure was
started, in an attempt to obtain lysis of the more recent
thrombus, superimposed on a chronic obstruction. In fact,
after the lytic therapy, we observed recanalization of the
brachiocephalic veins. Thereafter, the obstruction of the
SVC was treated with a balloon-expanding stent that
reached the maximum diameter a few days after the place-
ment.10 All reported studies agree that full heparinization is
mandatory, at least during the first 24 hours; however, to
date, no randomized controlled clinical trial has been per-
Fig 3. Final digital venography control after fibrinolysis and
stenting of the superior vena cava.formed to determine the need for anticoagulant treatmentand its duration.1,2,4,5,9 In our case, full anticoagulation
treatment was administered (intravenous heparin for the
first 48 hours and warfarin thereafter) to maintain more
than 1.5 times the normal values of the prothrombin time
and the activated partial prothrombin time. The stent is
highly thrombogenic in the first month, until neoendothe-
lium covers the endovascular superficies, and we agree that
anticoagulation is mandatory during this period. Currently,
we maintain anticoagulation for at least 6 months, or
longer if hypercoagulability is present. Possible recurrence
of SVCS treated with stents has been reported in up to 12%
of cases11; it is reported more frequently in the first month
after the procedure and is generally associated with previ-
ous thrombotic occlusion of the SVC. Recurrence of SVCS
was observed in this case 2 months after the procedure and
was probably related to patient noncompliance with the
pharmacologic therapy or to disease-related failure, because
the reocclusion was successfully restored with 24 hours’
infusion of urokinase. Several authors have reported that
complete remission was achieved within the first 24 to 48
hours in up to 90% of patients and that more than 83% of
patients were symptom free during the rest of the dis-
ease.9,12 In this case, the stented SVC remained patent at
the CT-A follow-up scan 36 months after the procedure.
CONCLUSION
Whether stent placement in patients with nonmalignant
SVCS should now be considered as the treatment of first
choice is still debatable because of the need for repeated
interventions. Nevertheless, in our experience, the clinical
outcome was satisfactory, because the most distressing symp-
toms disappeared, thus allowing the patient to comply with
the subsequent therapy treatment schedule. It could be a
viable and effective procedure in the hands of an experienced
team, achieving immediate excellent results with rapid and
prolonged remission of symptoms and few complications.
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